• SENSEX 74,660.02
    -121.74 (--0.16%)
  • BANKNIFTY 56,606.55
    134.60 (+0.24%)
  • HDFC Bank
    730.30 1,020.35(%)
  • Raymond
    1,121.80 1,024.00(%)
  • Solar Industries
    19,450.15 11,641.10(%)
  • Zensar Tech.
    479.80 868.50(%)
  • Infosys
    1,097.40 1,727.85(%)
  • Tata Inv.Corpn.
    750.30 1,184.00(%)
  • ESDS Software
    1,802.15 1,716.35(%)
  • TCS
    2,322.50 3,336.70(%)
  • Pine Labs
    191.50 134.75(%)
  • Reliance Industries
    1,249.00 1,250.55(%)
  • Netweb Technol.
    4,682.85 2,820.80(%)
  • Gland Pharma
    2,882.00 1,575.00(%)
  • Bharat Electron
    387.65 380.35(%)
  • Afcons Infrastr.
    304.70 479.05(%)
  • HCL Technologies
    1,290.10 1,770.00(%)
  • Coforge
    1,784.00 1,008.50(%)
  • SBI
    979.80 816.25(%)
  • IFCI
    78.12 46.20(%)
  • Piramal Finance.
    2,236.40 1,235.15(%)
  • Dhoot Transmission
    1,554.65 1,130.50(%)
  • Overview
  • Key Ratios
  • Financials
  • Shareholding
  • Company Info
  • Peer Comparison
Overview
  • Overview
  • Key Ratios
  • Financials
  • Shareholding
  • Company Info
  • Peer Comparison

Bafna Pharmaceuticals Ltd Pharmaceuticals - Indian - Formulations

  • Indian Private
  • BSE Code : 28611.0
  • ISIN : INE878I01022
301.45 -6 (-2.00%)
  • As on 15 Sep 2026 (EOD)

  • Today’s Low

    301.45

  • Today’s High

    301.45

  • Open

    301.45

  • Perv Close

    307.60

  • 52W Low

    94.77

  • 52W High

    318.50

Key Indicators

  • P/E(TTM)

    92.10

  • Mar.Cap (₹Cr.)

    713.12

  • Div & Yield %

    0.00

  • Book Value(₹)

    40.64

  • Debt-Equity Ratio

    -2.00

  • AGM Date

    11-Sep-2026

  • EPS

    3.29

  • P/E Ratio

    92.10

Financials Ratios

  • Debt-Equity Ratio

    -

  • Mar.Cap (₹Cr.)

    713.12

  • RONW (%)

    -

  • ROCE (%)

    -

Score Board

  • Equity (₹ in Cr.)

    23.66

  • BV (₹)

    40.60

  • Sales( ₹ in Cr.)

    150.62

  • NP (in Cr.)

    11.10

  • NP Var(%)

    74.0

  • Div%

    0.0

  • CPS (₹)

    7.30

  • EPS (₹)

    4.70

  • Traded Value (₹ in Lakhs)

    716.79

  • 52 Week High

    318.50

  • 52 Week Low

    94.77

  • Price BSE

    303.0

  • Price NSE

    301.00

  • Market Capital( in Cr.)

    716.79

  • P/C Ratio

    41.70

  • P/E Ratio

    64.60

  • Price Vs.BV

    4.70

View More
Invest Now!

Navigate The Market With Confidence

Your all-in-one destination for expert investment guidance and streamlined portfolio management solutions

Financials

All Values are in (₹Cr)
Particulars(INCOME) 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar
INCOME :            
Sales Turnover 150.62 145.86 152.47 115.35 85.14 71.22
Excise Duty 0.00 0.00 0.00 0.00 0.00 0.00
Net Sales 150.62 145.86 152.47 115.35 85.14 71.22
Other Income 4.76 2.74 3.52 3.27 1.70 0.75
Stock Adjustments 0.16 -6.45 4.85 2.91 1.77 -2.95
Total Income 155.54 142.15 160.84 121.53 88.61 69.02
EXPENDITURE :            
Raw Materials 82.14 74.49 91.58 65.98 41.70 33.58
Power and Fuel Cost 7.30 7.72 6.73 5.31 3.93 2.95
Employee Cost 21.92 21.03 19.03 15.87 14.65 11.98
Other Manufacturing Expenses 13.52 14.83 13.83 8.68 7.72 6.72
Selling and Administration Expenses 9.56 9.37 13.98 5.39 6.92 2.67
Miscellaneous Expenses 0.40 2.94 1.06 1.33 2.19 0.07
Employee Benefit Expenses 21.92 21.03 19.03 15.87 14.65 11.98
Less: Preoperative Expenditure 0.00 0.00 0.00 0.00 0.00 0.00
Total Expenses 134.83 130.38 146.20 102.55 77.11 57.97
Operating Profit 20.70 11.77 14.63 18.99 11.50 11.04
Interest 3.66 2.73 2.29 2.04 0.79 0.74
Gross Profit 17.04 9.04 12.34 16.95 10.71 10.30
Depreciation 6.07 4.89 5.00 5.33 5.49 4.48
Profit Before Tax 10.97 4.15 7.34 11.62 5.22 5.82
Current Tax -0.13 0.00 0.00 0.28 0.00 0.00
Fringe Benefit tax 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00
Reported Net Profit 11.10 4.15 7.35 11.34 5.22 5.83
Extraordinary Items 0.00 -2.22 0.07 0.20 -2.16 0.00
Adjusted Net Profit 11.10 6.37 7.28 11.14 7.38 5.83
Adjustment below Net Profit 0.00 0.00 0.04 0.15 -0.02 0.00
P & L Balance brought forward -43.11 -47.26 -54.48 -65.97 -71.17 -76.99
Statutory Appropriations 0.00 0.00 0.00 0.00 0.00 0.00
Appropriations 0.00 0.00 0.00 0.00 0.00 0.00
P & L Balance carried down -32.01 -43.11 -47.10 -54.48 -65.97 -71.17
Dividend 0.00 0.00 0.00 0.00 0.00 0.00
Preference Dividend 0.00 0.00 0.00 0.00 0.00 0.00
Equity Dividend (%) 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Per Share(Rs) 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Per Share-Unit Curr 4.69 1.76 3.11 4.79 2.21 2.46
Earnings Per Share(Adj)-Unit Curr 4.69 1.76 3.11 4.79 2.21 2.46
Book Value 40.64 35.85 34.17 31.05 26.19 24.00
Book Value(Adj)-Unit Curr 40.64 35.85 34.17 31.05 26.19 24.00

Shareholding Pattern

  • Promoter Group

    75.00%

  • Public Share Holding

    25.00%

Category of Shareholder No of Shares % Holdings Demat Shares Shareholders
A]. Promoter & Group
Foreign (Promoter & Group) - Bodies Corporate 0 0.00 0 0
Foreign (Promoter & Group)-Individuals (Non-Resident / Foreign) 0 0.00 0 0
Foreign Promoter(Institutional) 0 0.00 0 0
Promoter Others 0 0.00 0 0
Sub Total 0 0.00 0 0
[2] INDIAN
Bodies Corporate-Indian (Promoter & Group) 17,640,016 74.57 17,640,016 1
Government(Central / State)-Indian (Promoter & Group) 0 0.00 0 0
Directors & their Relatives-Indian (Promoter & Group) 1,989 0.01 1,989 1
Financial Institutions / Banks-Indian (Promoter & Group) 0 0.00 0 0
Individuals / Hindu Undivided Family-Indian (Promoter & Group) 100,246 0.42 100,246 5
Partnership Firms-Indian (Promoter & Group) 0 0.00 0 0
Persons Acting in Concert 0 0.00 0 0
Trusts 0 0.00 0 0
Others 0 0.00 0 0
Sub Total 17,742,251 75.00 17,742,251 7
Total ShareHolding for Promoter & Group
B]. Publice Share Holding
1] Institution
Government(Central / State) 0 0.00 0 0
Clearing Members 0 0.00 0 0
Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
Financial Institutions / Banks 0 0.00 0 0
Foreign Bank 0 0.00 0 0
Foreign Bodies Corporate/OCBs/FBC 0 0.00 0 0
Foreign Collaborators 0 0.00 0 0
Foreign Institutional Investors 2,209,803 9.34 2,209,803 3
Foreign Venture Capital Investors 0 0.00 0 0
Foreign Institution Other 0 0.00 0 0
Insurance Companies 0 0.00 0 0
Mutual Funds / UTI 0 0.00 0 0
Individuals (Non-Resident / Foreign) 0 0.00 0 0
NSDL Intransit 0 0.00 0 0
Others 0 0.00 0 0
Trusts 0 0.00 0 0
Venture Capital Funds 0 0.00 0 0
Sub total 2,209,803 9.34 2,209,803 3
2] Non Institution
Bodies Corporate 593,284 2.51 592,784 54
Clearing Members 0 0.00 0 0
Directors of their Relatives 0 0.00 0 0
Employees 0 0.00 0 0
Escrow Account 0 0.00 0 0
Foreign Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
NRIs/Foreign Individuals/Foreign Nationals 128,675 0.54 128,675 70
Foreign Non Institution Other 0 0.00 0 0
Hindu Undivided Families 147,997 0.63 147,997 214
Indian Public 0 0.00 0 0
Individuals holding nominal share capital in excess of Rs. 1 lakh 1,653,549 6.99 1,653,549 13
Individuals holding nominal share capital up to Rs. 1 lakh 1,178,611 4.98 1,172,071 6,696
Market Maker 0 0.00 0 0
NSDL Transit 0 0.00 0 0
Shares in transit 0 0.00 0 0
Societies 0 0.00 0 0
Trust & Foundation 0 0.00 0 0
Others 2,137 0.01 2,137 1
Sub Total 3,704,281 15.66 3,697,241 7,052
Total Public Shareholding
C]. Shares held by Custodians and against which Depository Receipts have been issued
ADR 0 0.00 0 0
GDR 0 0.00 0 0
Other Custodians 0 0.00 0 0
Total Shares held by Custodians and against which Depository Receipts have been issued 0 0.00 0 0
Grand Total ( A + B + C ) 23,656,335 100.00 23,649,295 7,062

Company Background

Bafna Pharmaceuticals LtdPharmaceuticals - Indian - Formulations

  • Bafna Pharmaceuticals Ltd
  • BSE Code : 28611.0
  • ISIN : INE878I01022

  • Incorporation Year

    1995

  • Registered Office

    Bafna Towers New No 68
    Old No 299 Thambu Chetty St, Chennai,
    Tamil Nadu-600001

  • Telephone

    91-44-25267517/25270992/4267755

  • FAX

    91-44-25231264/42677599

  • Chairman

    Ravichandran Chitra

  • Managing Director

  • Company Secretary

    A Mohanachandran

  • Auditor

    Brahmayya & Co

  • Face Value

    10

  • Listing

    NSE

  • Registrar

    Cameo Corporate Services Ltd
    Subramanian Building,
    V Floor,1 Club House Road
    Mumbai - Chennai - 600 002

Bafna Pharmaceuticals Ltd Peer Comparison

Profit & Loss
Financial Ratios
Balance Sheet
Select Company Name LTP (₹) Revenue Sales P/E Ratio ROCE %
Bafna Pharma. 303.00 155.37 150.62 92.10 8.91
Abbott India 25,586.10 7,217.19 6,929.05 33.67 43.78
Astrazeneca Phar 6,785.35 2,304.07 2,275.58 100.01 27.86
Glaxosmi. Pharma 2,837.20 3,932.76 3,790.20 45.32 58.17
Novartis India 2,393.15 393.10 354.33 60.43 15.94
Cipla 1,365.00 20,102.60 18,979.95 35.87 13.88
Bliss GVS Pharma 722.45 773.53 729.81 67.14 12.51
Amrutanjan Healt 490.35 520.13 502.55 26.26 24.16
Fermenta Biotec. 475.05 474.15 450.25 22.18 18.77
Guj. Themis Bio. 423.35 168.25 165.82 113.20 18.05
Ambalal Sarabhai 40.61 19.52 3.94 75.20 6.77